Endocrine Abstracts

The prevalence of antithyroid autoantibodies in pregnant women ranges between 6 and 10%, like in the general population. PPT, a syndrome of transient or permanent thyroid dysfunction occurring in the first year after delivery, is associated with the presence of TPO in gestation. The prevalence varies from 5 to 10%, with higher frequency in patients with DM1. The aim of this study is to estimate TPO frequency during gestation and its relationship with PPT in a group of women wi...

Aim: To analyze the influence of bariatric surgery over serum lipids in patients with morbid obesity after 1 year of surgery.Methods: Retrospective study of 88 patients before and after 1 year of bariatric surgery (65 by pass and 23 sleeve). We collected data about age, sex, other diseases, anthropometric measures and biochemical parameters: glucose, uric acid, total cholesterol (TC), HDL-C, LDL-C, triglycerides (TG), VLDL and non-HDL-C, homocistein and ...

We present the clinical case of a family with an initial diagnosis of AIP syndrome with AIP mutation and a secondary diagnosis of MEN syndrome associated because of a large MEN-1 gen deletion. A male patient 16 years old was evaluated because of delayed growth and pubertal development. He had headaches, nausea and vomits since seven years old. MRI showed: Large pituitary mass of 47.6×22×47.2 mm that erode the floor of the sella, extending into the left prepontine cis...

Introduction: Amiodarone is an excellent antiarrhythmic with a high use although it isn’t free from complications. Most of patients stay euthyroid (80%), inducing thyroid dysfunction in the remaining 20% (thyrotoxicosis, 1.5–3%).Objective: We analyze amiodarona-associated hyperthyroidism surgical management according to the associated pathology and patients clinical evolution.Subjects and methods: We report four patients ...

Introduction: Adrenocortical carcinoma (ACC) is a rare and aggressive tumor that accounts for 0.2% of cancer-related deaths. Case series and prospective studies are very limited due to its low prevalence. Current knowledge is based primarily on the opinions of experts in specialized units. The aim of this study is to perform a descriptive analysis of the management and prognosis of patients with ACC in HCSC in the last 20 years.Material and methods: Eigh...

Introduction: This study aimed to determine the timeframe to achieve hormonal normalization considering dosing patterns of Somatuline Autogel (SOM, lanreotide) used in clinical practice.Methods: From March 2013 to October 2013 clinical data from 62 patients with active acromegaly treated with SOM for &gE;4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalised IGF1 on &gE;two evaluations) at 17 Spanish hospitals were collected i...

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...

Pharmacologic treatment of acromegaly is currently based upon assay-error strategy in which first generation somatostatin analogs (SSA) is the first-line treatment. However, about 50% of patients do no respond adequately to SSA. We aimed to evaluate the potential usefulness of including studies of molecular markers identifying poor response to SSA for prescription of pharmacologic treatment in acromegalic patients in which SSA was prescribed before surgical therapy.<p clas...